H.-H. Neumayer

724 total citations
24 papers, 560 citations indexed

About

H.-H. Neumayer is a scholar working on Transplantation, Pediatrics, Perinatology and Child Health and Surgery. According to data from OpenAlex, H.-H. Neumayer has authored 24 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Transplantation, 7 papers in Pediatrics, Perinatology and Child Health and 5 papers in Surgery. Recurrent topics in H.-H. Neumayer's work include Renal Transplantation Outcomes and Treatments (12 papers), Pharmacological Effects and Toxicity Studies (6 papers) and Metabolism and Genetic Disorders (3 papers). H.-H. Neumayer is often cited by papers focused on Renal Transplantation Outcomes and Treatments (12 papers), Pharmacological Effects and Toxicity Studies (6 papers) and Metabolism and Genetic Disorders (3 papers). H.-H. Neumayer collaborates with scholars based in Germany, United Kingdom and Spain. H.-H. Neumayer's co-authors include Klemens Budde, Kim C. Wagner, Ingrid Mai, H. Krüger, Karsten Midtvedt, Ivar Roots, Andreas Johne, Elke Störmer, Steffen Bauer and Johannes Waiser and has published in prestigious journals such as The Journal of Urology, Transplantation and Nephrology Dialysis Transplantation.

In The Last Decade

H.-H. Neumayer

23 papers receiving 532 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H.-H. Neumayer Germany 11 193 164 116 96 79 24 560
Muhammad S. Yaqub United States 14 85 0.4× 209 1.3× 212 1.8× 36 0.4× 34 0.4× 43 592
S. Madsen Denmark 11 159 0.8× 210 1.3× 288 2.5× 71 0.7× 42 0.5× 47 648
A. E. Lison Germany 8 32 0.2× 157 1.0× 115 1.0× 95 1.0× 63 0.8× 25 457
P. Evenepoel Belgium 11 466 2.4× 163 1.0× 133 1.1× 105 1.1× 107 1.4× 12 787
Edyta Gołembiewska Poland 11 189 1.0× 30 0.2× 81 0.7× 30 0.3× 36 0.5× 55 488
I Lampreabe Spain 11 98 0.5× 183 1.1× 180 1.6× 39 0.4× 15 0.2× 25 457
Beverley L. Ketel United States 12 28 0.1× 115 0.7× 144 1.2× 63 0.7× 10 0.1× 26 640
James A. Pederson United States 13 228 1.2× 19 0.1× 78 0.7× 74 0.8× 55 0.7× 24 516
Se-Hee Yoon South Korea 13 101 0.5× 82 0.5× 46 0.4× 46 0.5× 13 0.2× 43 404
Bennett Wm United States 15 157 0.8× 59 0.4× 67 0.6× 86 0.9× 26 0.3× 36 529

Countries citing papers authored by H.-H. Neumayer

Since Specialization
Citations

This map shows the geographic impact of H.-H. Neumayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.-H. Neumayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.-H. Neumayer more than expected).

Fields of papers citing papers by H.-H. Neumayer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.-H. Neumayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.-H. Neumayer. The network helps show where H.-H. Neumayer may publish in the future.

Co-authorship network of co-authors of H.-H. Neumayer

This figure shows the co-authorship network connecting the top 25 collaborators of H.-H. Neumayer. A scholar is included among the top collaborators of H.-H. Neumayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.-H. Neumayer. H.-H. Neumayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kron, Susanne, et al.. (2011). Extended daily on-line high-volume haemodiafiltration in septic multiple organ failure: a well-tolerated and feasible procedure. Nephrology Dialysis Transplantation. 27(1). 146–152. 27 indexed citations
3.
Fassbinder, W, et al.. (2008). Prävalenz von Antikörpern gegen LAV/HTLV-III bei terminal niereninsuffizienten Patienten unter Hämodialysebehandlung und nach Nierentransplantation. DMW - Deutsche Medizinische Wochenschrift. 111(28/29). 1087–1090.
4.
Haase, Michael, Rinaldo Bellomo, Ian T. Baldwin, et al.. (2007). β2-Microglobulin Removal and Plasma Albumin Levels with High Cut-off Hemodialysis. The International Journal of Artificial Organs. 30(5). 385–392. 14 indexed citations
5.
Budde, Klemens, Petra Glander, Fritz Diekmann, et al.. (2004). Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients. Transplantation Proceedings. 36(2). S524–S527. 14 indexed citations
6.
Fangmann, J., Wolfgang Arns, Hans‐Peter Marti, et al.. (2004). IMPACT OF DACLIZUMAB AND LOW DOSE CYCLOSPORINE IN COMBINATION WITH MYCOPHENOLATE MOFETIL AND STEROIDS ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION. Transplantation. 78. 280–281. 4 indexed citations
7.
Braun, J., H. Hölzer, R. Brunkhorst, et al.. (2004). Long-term comparison of a calcium-free phosphate binder and calcium carbonate - phosphorus metabolism and cardiovascular calcification. Clinical Nephrology. 62(8). 104–115. 121 indexed citations
8.
Dragun, Duska, et al.. (2004). FTY720: early clinical experience. Transplantation Proceedings. 36(2). S544–S548. 17 indexed citations
9.
Bauer, Steffen, Elke Störmer, Andreas Johne, et al.. (2003). Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. British Journal of Clinical Pharmacology. 55(2). 203–211. 128 indexed citations
10.
Einecke, Gunilla, Ingrid Mai, Fritz Diekmann, et al.. (2002). Cyclosporine absorption profiling and therapeutic drug monitoring using c2 blood levels in stable renal allograft recipients. Transplantation Proceedings. 34(5). 1738–1739. 17 indexed citations
11.
Schachschal, Guido, et al.. (2002). Emerging indications for MARS® dialysis. Liver International. 22(s2). 63–68. 7 indexed citations
12.
Einecke, Gunilla, Ingrid Mai, Fritz Diekmann, et al.. (2001). Optimizing neoral therapeutic drug monitoring with cyclosporine trough (C0) and C2 concentrations in stable renal allograft recipients. Transplantation Proceedings. 33(7-8). 3102–3103. 8 indexed citations
13.
Fritsche, Lutz, Yves Vanrenterghem, J. M. Grinyó, et al.. (2000). Different diagnostic approaches to adult candidates for cadaveric kidney transplantation in Europe. Transplant International. 13(S1). S263–S266. 1 indexed citations
14.
Budde, Klemens, Lutz Fritsche, B. Schönberger, et al.. (1998). Tacrolimus Rescue Therapy in Late Rejection After Renal Transplantation: Outcome After 18 Months. Transplantation Proceedings. 30(4). 1238–1239. 2 indexed citations
15.
Frei, Ulrich, H.-H. Neumayer, B. Buchholz, D. Niese, & E. Mueller. (1998). Randomized, Double-Blind, One-Year Study of the Safety and Tolerability of Cyclosporine Microemulsion Compared With Conventional Cyclosporine in Renal Transplant Patients. The Journal of Urology. 160(6 Part 1). 2300–2300. 1 indexed citations
16.
Claesson, Kerstin, A. David Mayer, J.P. Squifflet, et al.. (1998). Lipoprotein Patterns in Renal Transplant Patients: A Comparison Between FK 506 and Cyclosporine A Patients. Transplantation Proceedings. 30(4). 1292–1294. 45 indexed citations
17.
Waiser, Johannes, et al.. (1997). Interleukin-6 expression after renal transplantation. Nephrology Dialysis Transplantation. 12(4). 753–759. 67 indexed citations
18.
Neumayer, H.-H., L. Färber, Klemens Budde, et al.. (1996). Long-term results of conversion from existing to microemulsion formulation of cyclosporine.. PubMed. 28(4). 2207–13. 2 indexed citations
19.
Schott, G., et al.. (1994). [Kidney transplantation in patients with anomalies of the lower urinary tract].. PubMed. 33(5). 401–14. 2 indexed citations
20.
Neumayer, H.-H. & Kim C. Wagner. (1987). Prevention of delayed graft function in cadaver kidney transplants by diltiazem: outcome of two prospective, randomized clinical trials.. PubMed. 10 Suppl 10. S170–7. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Muhammad S. Yaqub Breakdown of academic impact, for papers by S. Madsen Breakdown of academic impact, for papers by A. E. Lison Breakdown of academic impact, for papers by P. Evenepoel Breakdown of academic impact, for papers by Edyta Gołembiewska Breakdown of academic impact, for papers by I Lampreabe Breakdown of academic impact, for papers by Beverley L. Ketel Breakdown of academic impact, for papers by James A. Pederson Breakdown of academic impact, for papers by Se-Hee Yoon Breakdown of academic impact, for papers by Bennett Wm
Rankless by CCL
2026